ExploreWatchlistsPricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. Gross profit

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥4.9B
P/E ratio
-3.9x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Mar 31, 20260-95.10%
Mar 31, 20251+1938.89%
Mar 31, 20240-98.40%
Mar 31, 20233-72.01%
Mar 31, 202212+790.35%
Mar 31, 20211-80.12%
Mar 31, 20207-91.97%
Mar 31, 201985+116.91%
Mar 31, 201839+734.96%
Mar 31, 20175-90.77%
Mar 31, 201651-7.47%
Mar 31, 201555

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat